The broad objective of this proposal is to develop the University of California, Irvine (UCI) as an institution strong and productive in the performance of cooperative group trials.
The specific aims i nclude: (1) establishment of a high quality, productive clinical oncology trials effort at the University of California, Irvine, (2) expansion of clinical oncology trials to Orange County (and environs) CGOPs and Satellite Affiliates that use the University of California, Irvine as its SWOG institutional base, (3) recruitment of fully eligible patients into SWOG cooperative group phase II and III trials, (4) recruitment of at least a proportionate number of Hispanic, Asian, and socioeconomically disadvantaged patients into clinical oncology trials, (5) continued ongoing quality assurance program for trials conducted both on-site and off-site. Participation in SWOG trials represents a carefully crafted program in clinical research at the UCI Clinical Cancer Center. The conduct of trials is coordinated through a Clinical Trials Coordinator and data management staff under the day-to-day direction of biostatistician. Recruitment strategies, procedures for eligibility, evaluation, and follow-up, IRB issues and method of procedures have been standardized. CGOPs have been established at three large community hospitals. Additionally, Satellite Affiliates have been established with clinical faculty in Orange County and Long Beach. We have created an active Patient Advocacy Committee and recruitment of minorities and socioeconomically deprived individuals into trials is an important function. The initial effort has been successful and we plan to recruit a minimum of 100 patients per year into SWOG clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA058723-01A1
Application #
3559030
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-08-01
Project End
1997-12-31
Budget Start
1993-08-01
Budget End
1993-12-31
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of California Irvine
Department
Type
Schools of Medicine
DUNS #
161202122
City
Irvine
State
CA
Country
United States
Zip Code
92697
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Press, Oliver W; Unger, Joseph M; Rimsza, Lisa M et al. (2013) A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res 19:6624-32

Showing the most recent 10 out of 75 publications